Differences in prognosis of colorectal cancer patients based on the expression of sialyl Lewisa, sialyl Lewisx and sialyl Tn antigens in serum and tumor tissue.
OBJECTIVE
To clarify the differences in prognosis of colorectal cancer patients based on the expression of sialyl Lewisaa sialyl Lewisx and sialyl Tn antigens in serum and tumor tissue.


METHODS
Preoperative serum levels (by radioimmunoassay) and tumor tissue expression (by immunohistochemistry) of these antigens were simultaneously determined in 52 patients. For each antigen, patients were classified into one of four groups: Group S-/T-, S-/T+, S+/T- and S+/T+. (S denotes serum, T denotes tumor tissue, and negative and positive represent expression).


RESULTS
For sialyl Lewisa antigen, the survival time of Group S+/T+ was significantly shorter than Group S-/T- or Group S-/T+ (p=0.027 or p=0.032, respectively). For sialyl Lewisx antigen, the survival time of Group S-/T+ was significantly shorter than Group S-/T- (p=0.048).


CONCLUSIONS
Increased expressions of sialyl Lewisa antigen in serum and sialyl Lewisx antigen in tumor tissue may be associated with poor prognosis in colorectal cancer patients.
Akamine
Shinji
S
First Department of Surgery, Nagasaki University School of Medicine, Nagasaki, Japan. shinji@net.nagasaki-u.ac.jp
Nakagoe
Tohru
T
Sawai
Terumitsu
T
Tsuji
Takashi
T
Tanaka
Kenji
K
Hidaka
Shigekazu
S
Shibasaki
Shin-Ichi
S
Nanashima
Atsushi
A
Yamaguchi
Hiroyuki
H
Nagayasu
Takeshi
T
Yasutake
Toru
T
D000368:Aged; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000096:biosynthesis* / Q000097:blood; D014408:Biomarkers, Tumor / Q000096:biosynthesis* / Q000097:blood; D018395:CA-19-9 Antigen; D015179:Colorectal Neoplasms / Q000097:blood / Q000276:immunology* / Q000473:pathology / Q000601:surgery; D005260:Female; D005732:Gangliosides / Q000096:biosynthesis / Q000097:blood; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009844:Oligosaccharides / Q000096:biosynthesis / Q000097:blood; D011379:Prognosis; D011863:Radioimmunoassay; D000080506:Sialyl Lewis X Antigen; D015996:Survival Rate
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D005732:Gangliosides; D009844:Oligosaccharides; D000080506:Sialyl Lewis X Antigen; C055491:sialosyl-Tn antigen; C064564:sialyl Le(a) ganglioside